Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study
Significant increases in the risk of moderate and severe covid-19 outcomes occurred three months after primary vaccination with CoronaVac among people aged 65 and older, providing supportive evidence for the implementation of vaccine boosters in these populations who received this inactivated vaccine.
Conceptualizing “the end” of COVID-19: temporality and linear mobilization toward health
- MedicineReview of Communication
ABSTRACT COVID-19 has crystalized how Western sociopolitical, cultural, and biomedical understandings of health advance the spaciotemporal logic of “the end.” This logic defines health in terms of…
Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?
- MedicineMicrobial biotechnology
The evidence for efficacy of face mask wearing in various settings is reviewed and overall pooled analysis showed significant reduction in COVID‐19 incidence with mask wearing, although heterogeneity between studies was substantial.
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
- Biology, MedicineNature communications
We present an interim analysis of a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and…
Knowledge, Attitudes, and Practices of Adult Iraqi Population Towards COVID-19 Booster Dose: A Cross-Sectional Study
- MedicinePatient preference and adherence
Purpose COVID-19 vaccines are critical for containing the pandemic and preventing serious SARS-CoV-2 infections. In addition to the two main doses, a booster dose has been utilized to improve…
Immunogenicity following two doses of BBIBP-CorV vaccine and a third booster dose with viral vector and mRNA COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of BBIBP-CorV vaccine
- Biology, MedicinemedRxiv
Administration of the third dose with either viral vector or mRNA vaccine for the BBIBP-CorV-primed individuals to stimulate antibody and T cell responses is supported.
Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia
- MedicineClinical and Experimental Vaccine Research
Imaging Severity COVID-19 Assessment in Vaccinated and Unvaccinated Patients: Comparison of the Different Variants in a High Volume Italian Reference Center
- MedicineJournal of personalized medicine
In critically ill patients no difference was observed in terms of severity of disease or exitus, between unvaccinated and vaccinated patients, and the only statistically significant differences were observed, with regard to the severity of COVID-19 pulmonary parenchymal involvement.
A Testing and Quarantine Algorithm for Individual International Travelers Using Published Data on WHO-Approved Vaccines and Bayes’ Theorem
A negative preboarding test and a negative arrival test can ensure that a traveler has a lower expected transmission than an unvaccinated person who is quarantined for 14 days.
SHOWING 1-8 OF 8 REFERENCES
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
- Medicine, BiologymedRxiv
Insight is provided into the generation of long-term immunological memory by the inactivated vaccine, which has implications for future booster strategies that the frontline HCWs, individuals with low serological response to 2 dose of vaccine and immune compromised patients could benefit from a third dose of inactivation vaccine.
Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases
Despite varying effectiveness estimates, Brazil's population benefited from vaccination in preventing severe COVID-19 outcomes, suggesting significant vaccine-specific reductions in effectiveness by age, given by differences between age groups 60-79 years and over 80 years.
Heterologous prime-boost immunization with CoronaVac and Convidecia
The heterologous prime-boost regimen with Convidecia after the priming with CoronaVac was safe and significantly immunogenic than a homogeneous boost with Coronavac.
Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
Combination use of different available vaccines may be warranted in Thailand, which faces limited vaccine choice and supply, because of delayed mass-immunization of COVID-19 vaccines.
Short-Term Immune Response After Inactivated SARS-CoV-2 (CoronaVac, Sinovac) And ChAdOx1 nCoV-19 (Vaxzevria, Oxford-AstraZeneca) Vaccinations in Thai Health Care Workers
A rapid decline of short-term immune response in the HCWs after the SV vaccination indicates the need for a vaccine booster, particularly during the ongoing spreading of the SAR-CoV-2 variants of concern.
Comparison of the Immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong: An Observational Cohort Study
- MedicineSSRN Electronic Journal
Vaccination with BNT162b2 induces significantly higher levels of SARS-CoV-2 specific binding and neutralizing antibody responses compared to CoronaVac and these differences are likely to result in differences in protection from infection.
The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19).
The results suggest that individuals aged 90 years or older may benefit from an expedited third booster dose, and both vaccines demonstrated overall effectiveness against severe COVID-19 up to 80 years of age.
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Importance: Whether herd immunity through mass vaccination is sufficient to curb SARS-CoV-2 transmission requires an understanding of the duration of vaccine-induced immunity, and the necessity and…